The ONS antibody studies suggest that nearly half of 16 and 17 year olds have been previously infected. We don’t know the equivalent figure for 12 to fives but it is likely to be similar. That means the vaccine effect relative to all unvaccinated (previously infected and not) will be drastically lower than the figure used in the modelling paper. In turn, even the 15 minutes of prevented lost schooling will be a significant overestimate.
Julian Charles of The Mind Renewed podcast interviews Diny Fielder-van Kleeff from The Vaccine Control Group.
We are joined by the author Diny Fielder-van Kleeff, co-founder of the Vaccine Control Group—or, more fully, the SARS-CoV-2 Vaccine Control Group—for an in-depth interview on the aims and objectives of this intriguiging and potentially highly significant “community cooperative” study.
“The Vaccine Control Group is a worldwide independent long-term study that is seeking to provide a baseline of data from unvaccinated individuals for comparative analysis with the vaccinated population, to evaluate the success of the Covid-19 mass vaccination programme and assist future research projects. This study is not, and will never be, associated with any pharmaceutical enterprise as its impartiality is of paramount importance. The VaxControlGroup is a community cooperative, for the people. All monies raised will be re-invested into the project and its community.”—VaxControlGroup
Teenage boys are six times more likely to suffer from heart problems from the vaccine than be hospitalised from Covid-19, a major study has found.
Children who face the highest risk of a “cardiac adverse event” are boys aged between 12 and 15 following two doses of a vaccine, according to new research from the US.
JCVI member Professor Adam Finn said that the latest data from paediatric cardiologists in the US shows that there are concerns about the long-term side effects of COVID-19 vaccine for children.
We spoke to Professor Anthony Harnden, the deputy chair of the Joint Committee on Vaccination and Immunisation, and asked him why they had ruled out vaccines for healthy 12 to 15-year-olds.
The real-world study includes data on positive Covid PCR test results between May and July 2021 among more than a million people who had received two doses of Pfizer or AstraZeneca vaccine.
Protection after two shots of Pfizer decreased from 88% at one month to 74% at five to six months.
For AstraZeneca, the fall was from 77% to 67% at four to five months.
Pfizer’s Covid vaccine may pose more of a risk to boys, a study claimed today amid growing calls for No10 to rethink plans to dish out jabs to children.
New research has suggested boys are 14 times more likely to be struck down with a rare heart complication called myocarditis.
The data, from the US, will likely fuel an already fierce debate over Britain’s decision to press ahead with inoculating all 16 and 17-year-olds.
Children are being vaccinated against Covid before an official decision on whether youngsters should be given the jab, The Telegraph can disclose.
Councils and GPs in virus hotspots are defying current government rules by giving the vaccine to 16- and 17-year-olds without underlying health conditions.
One of the UK’s leading childhood health experts has said there is not enough evidence to support vaccinating children against Covid, and the body that will make the decision on whether to jab under-18s has indicated it will take a cautious approach.
Prof Calum Semple, a member of the Scientific Advisory Group for Emergencies (Sage), said there was “rock-solid data” to show that the risk of severe harm to children from Covid was “incredibly low”.
Professor Robert Dingwall said children may be “better protected by natural immunity generated through infection than by asking them to take the ‘possible’ risk of a vaccine”.
…On Wednesday, Prof Dingwall, a social scientist who sits on a subcommittee of the Scientific Advisory Group for Emergencies (Sage) as well as on the JCVI, spoke out, saying the “risk/benefit for teenagers must be firmly established” before any decisions were taken.
In a detailed Twitter thread, he said: “Teenagers are at intrinsically low risk from Covid. Vaccines must be exceptionally safe to beat this. Given the low risk of Covid for most teenagers, it is not immoral to think that they may be better protected by natural immunity generated through infection than by asking them to take the possible risk of a vaccine.”
Flu could be a “bigger problem” than Covid-19 this winter, the deputy chairman of the Joint Committee on Vaccination and Immunisation (JCVI) has warned.
Professor Anthony Harnden told BBC 4’s Today programme: “I will emphasise that actually flu could be potentially a bigger problem this winter than Covid.
“We’ve had a very, very low prevalence of flu for the last few years, particularly virtually nil during lockdown, and we do know that when flu has been circulating in very low numbers immunity drops in the population, and it comes back to bite us. So, flu can be really, really important this winter.”
Covid testing in schools is hugely disruptive and should be suspended, experts have said, as it emerged that up to 60 per cent of “positive” tests a week are coming back negative when checked.
Under plans to keep schools open, more than 50 million lateral flow tests have been carried out on youngsters, leading to thousands of pupils and their social bubbles being forced to self-isolate for 10 days.
Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.
The results also show that levels of these antibodies are lower with increasing age and that levels decline over time, providing additional evidence in support of plans to deliver a vaccination boost to vulnerable people in the Autumn.
In the case of single-dose recipients, our data show that NAbTs are significantly lower against B.1.617.2 and B.1.351 VOCs relative to B.1.1.7, implying that although a single dose might still afford considerably more protection than no vaccination, single-dose recipients are likely to be less protected against these SARS-CoV-2 variants. These data therefore suggest that the benefits of delaying the second dose, in terms of wider population coverage and increased individual NAbTs after the second dose,7 must now be weighed against decreased efficacy in the short-term, in the context of the spread of B.1.617.2. Worldwide, our data highlight the ongoing need to increase vaccine supply to allow all countries to extend second-dose protection as quickly as possible.
In the longer term, we note that both increased age and time since the second dose of BNT162b2 significantly correlate with decreased NAb activity against B.1.617.2 and B.1.351—both of which are also characteristic of the population in the UK at highest risk of severe COVID-19 (ie, older and vaccinated earlier), independent of other existing factors such as compromised immune status or comorbidity, or geographic-specific responses to vaccination.
A woman in her 30s has died from a stroke after the Oxford/AstraZeneca Covid vaccination caused a blood clot to form in an artery in her brain.
The patient, a 35-year-old Asian woman, went to hospital six days after her vaccine appointment, and died two weeks after being admitted following “extensive hemorrhaging”.
The Government is facing a backlash over plans to extend the vaccine rollout to children, with some experts questioning the benefits of the proposed move.
Dozens of medics, doctors and scientists have written to the Medicines and Healthcare products Regulatory Agency (MHRA) to express their “grave concern” over the proposals.
In a joint letter, they warned it is “irresponsible, unethical and unnecessary” to jab children and urged the medicines watchdog not to “repeat mistakes from history”.
THE influence of the Bill & Melinda Gates Foundation (GF) extends right into the heart of the British medical and science establishment. It has been funding British companies, charities, universities and public bodies for almost 25 years.
All under-40s are to be offered an alternative to the Oxford-AstraZeneca coronavirus vaccine as a precaution.
Practices will be paid £12.58 (€14.15; $16.69) per vaccination. This is 25% more than the current £10.06 practices receive for an influenza vaccination, in recognition of the need for extra training, post-vaccine observation, and other associated costs. Practices will need to provide most of the required staff from their own workforce.